Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

Stock Information for Safe Pro Group Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Safe Pro Group Inc.

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13
Vaxart to Present at the Citizens Life Sciences Conference
Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate
Vaxartto Present at World Vaccine Congress Washington 2025 on April 23
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart Provides Business Update and Reports Full Year 2024 Financial Results
Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.